Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.

[1]  G. Filippatos,et al.  Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. , 2020, The New England journal of medicine.

[2]  S. Daskalopoulou,et al.  Hypertension Canada's 2020 Evidence Review and Guidelines for the Management of Resistant Hypertension. , 2020, The Canadian journal of cardiology.

[3]  J. Williamson,et al.  Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial , 2019, JAMA.

[4]  Thomas Kahan,et al.  [2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)]. , 2018, Giornale italiano di cardiologia.

[5]  P. Whelton,et al.  Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT , 2018, Journal of the American Heart Association.

[6]  Jackson T. Wright,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American College of Cardiology.

[7]  Alexander G Logan,et al.  Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. , 2018, The Canadian journal of cardiology.

[8]  P. Whelton,et al.  Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney Disease: A Secondary Analysis of a Randomized Trial. , 2017, Annals of internal medicine.

[9]  Jackson T. Wright,et al.  Effects of Intensive BP Control in CKD. , 2017, Journal of the American Society of Nephrology : JASN.

[10]  James R. Powell,et al.  Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial , 2017, Diabetes Care.

[11]  Jenny I. Shen,et al.  Toward Establishing Core Outcome Domains For Trials in Kidney Transplantation: Report of the Standardized Outcomes in Nephrology—Kidney Transplantation Consensus Workshops , 2017, Transplantation.

[12]  V. Perkovic,et al.  Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  S. Anderson,et al.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.

[14]  M. Shlipak,et al.  Effect of Intensive Versus Usual Blood Pressure Control on Kidney Function Among Individuals With Prior Lacunar Stroke: A Post Hoc Analysis of the Secondary Prevention of Small Subcortical Strokes (SPS3) Randomized Trial. , 2016, Circulation.

[15]  C. Escobar Cervantes,et al.  [A randomized trial of intensive versus standard blood pressure control]. , 2016, Semergen.

[16]  Jackson T. Wright,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[17]  M. Woodward,et al.  Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials , 2013, BMJ.

[18]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[19]  芳充 後藤.  海外論文紹介 : Strict Blood-Pressure Control and Progression of Renal Failure in Children , 2010 .

[20]  A. Anarat,et al.  Strict blood-pressure control and progression of renal failure in children. , 2009, The New England journal of medicine.

[21]  Di Xie,et al.  Efficacy and safety of benazepril for advanced chronic renal insufficiency. , 2006, The New England journal of medicine.

[22]  G. Remuzzi,et al.  Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial , 2005, The Lancet.

[23]  Tom Greene,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.

[24]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[25]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[26]  Giuseppe Remuzzi,et al.  Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria , 1999, The Lancet.

[27]  The Gisen Group.  Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy , 1997, The Lancet.

[28]  F. Locatelli,et al.  Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency , 1996 .

[29]  G. Beck,et al.  The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease , 1994 .

[30]  George W. Williams,et al.  The modification of diet in renal disease study group , 1991 .